Orchard Therapeutics plc
ORTXNASDAQHealthcare
$16.70
+$0.05(+0.30%)
Market Cap$380108700
P/E Ratio—
52W High$16.72
52W Low$4.24
Orchard Therapeutics plc (ORTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ORTX · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2024Report Date: Mar 4, 2024EPS Actual
-$0.60
Est. -$2.10 · +71.4%
Revenue
—
Est. $0.01B
Fiscal Period
Q1 FY2024
FY ends December
Report Date
Mar 4, 2024
After Market Close
▲ Beat EPS🔥 5-Quarter EPS Beat Streak
ORTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2024 | Aug 3, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | May 13, 2024 | — | — | — | — | — | — |
| ▲ Q1 FY2024 | Mar 4, 2024 | -$2.10 | -$0.60 | +71.4% | — | $0.01B | — |
| ▲ Q4 FY2023 | Nov 13, 2023 | -$1.30 | -$0.15 | +88.5% | $0.01B | $0.01B | -35.5% |
| ▲ Q3 FY2023 | Aug 3, 2023 | -$1.67 | -$0.07 | +95.8% | $0.01B | $0.01B | -11.0% |
| ▲ Q2 FY2023 | May 15, 2023 | -$1.78 | -$0.12 | +93.3% | $0.00B | $0.01B | -81.1% |
| ▲ Q1 FY2023 | Mar 6, 2023 | -$1.80 | -$0.60 | +66.7% | $0.01B | $0.01B | +16.2% |
| ▼ Q4 FY2022 | Nov 14, 2022 | -$2.30 | -$3.70 | -60.9% | $0.01B | — | — |
Q3 FY2024
Aug 3, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 13, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 4, 2024Beat
EPS Actual
-$0.60
EPS Est.
-$2.10
EPS Surpr.
+71.4%
Revenue
—
Q4 FY2023
Nov 13, 2023Beat
EPS Actual
-$0.15
EPS Est.
-$1.30
EPS Surpr.
+88.5%
Revenue
$0.01B
Q3 FY2023
Aug 3, 2023Beat
EPS Actual
-$0.07
EPS Est.
-$1.67
EPS Surpr.
+95.8%
Revenue
$0.01B
Q2 FY2023
May 15, 2023Beat
EPS Actual
-$0.12
EPS Est.
-$1.78
EPS Surpr.
+93.3%
Revenue
$0.00B
Q1 FY2023
Mar 6, 2023Beat
EPS Actual
-$0.60
EPS Est.
-$1.80
EPS Surpr.
+66.7%
Revenue
$0.01B
Q4 FY2022
Nov 14, 2022Miss
EPS Actual
-$3.70
EPS Est.
-$2.30
EPS Surpr.
-60.9%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $2.33 | $1.54 | $0.75 | 0 |
| Q2 FY2024 | $2.03 | $1.34 | $0.65 | 0 |
| Q1 FY2024 | $2.38 | $1.57 | $0.77 | 1 |
| Q4 FY2023 | $-2.10 | $-1.55 | $-1.00 | 1 |
| Q3 FY2023 | $-1.60 | $-1.30 | $-1.10 | 2 |
| Q2 FY2023 | $-2.53 | $-1.67 | $-0.82 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2024 | Mar 4, 2024 | +71.4% | $16.70 | — | — |
| ▲ Q4 FY2023 | Nov 13, 2023 | +88.5% | $15.98 | $15.95 | -0.19% |
| ▲ Q3 FY2023 | Aug 3, 2023 | +95.8% | $5.08 | $5.23 | +2.95% |
| ▲ Q2 FY2023 | May 15, 2023 | +93.3% | $5.14 | $5.38 | +4.67% |
| ▲ Q1 FY2023 | Mar 6, 2023 | +66.7% | $4.80 | $5.50 | +14.58% |
| ▼ Q4 FY2022 | Nov 14, 2022 | -60.9% | $4.70 | $4.50 | -4.26% |
| ▼ Q3 FY2022 | Aug 4, 2022 | -60.0% | $5.40 | $5.30 | -1.85% |
| ▼ Q2 FY2022 | May 12, 2022 | -40.0% | $4.40 | $4.20 | -4.55% |
Q1 FY2024—
Report Date
Mar 4, 2024
EPS Beat/Miss
+71.4%
Price Before
$16.70
Price After
—
Q4 FY2023-0.19%
Report Date
Nov 13, 2023
EPS Beat/Miss
+88.5%
Price Before
$15.98
Price After
$15.95
Q3 FY2023+2.95%
Report Date
Aug 3, 2023
EPS Beat/Miss
+95.8%
Price Before
$5.08
Price After
$5.23
Q2 FY2023+4.67%
Report Date
May 15, 2023
EPS Beat/Miss
+93.3%
Price Before
$5.14
Price After
$5.38
Q1 FY2023+14.58%
Report Date
Mar 6, 2023
EPS Beat/Miss
+66.7%
Price Before
$4.80
Price After
$5.50
Q4 FY2022-4.26%
Report Date
Nov 14, 2022
EPS Beat/Miss
-60.9%
Price Before
$4.70
Price After
$4.50
Q3 FY2022-1.85%
Report Date
Aug 4, 2022
EPS Beat/Miss
-60.0%
Price Before
$5.40
Price After
$5.30
Q2 FY2022-4.55%
Report Date
May 12, 2022
EPS Beat/Miss
-40.0%
Price Before
$4.40
Price After
$4.20
Avg Beat Reaction+5.50%
Avg Miss Reaction-3.55%
Beat Rate5 / 8 quarters
Largest Move+14.58% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ORTX ends December
Orchard Therapeutics plc (ORTX) most recently reported earnings on March 4, 2024 for Q1 FY2024, posting EPS of $-0.60 — beating the analyst consensus of $-2.10 by +71.4%. ORTX has beaten EPS estimates for 5 consecutive quarters. The next ORTX earnings date is expected around September 1, 2026.
Each quarter, investors track ORTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ORTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ORTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ORTX earnings · 5 questionsOrchard Therapeutics plc's next earnings report is expected around September 1, 2026. ORTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ORTX historically reports after market close (AMC).
ORTX earnings datewhen is ORTX earningsORTX next earnings datewhen does ORTX report earningsORTX earnings calendar
▸ Source: FMP · Orchard Therapeutics plc SEC filings · US GAAP · Orchard Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026